CA9

Arsenal Biosciences Announces Presentation of Four Abstracts at AACR Annual Meeting Highlighting New CAR T-Focused Research

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Ovarian cancer, Short interspersed nuclear element, B cell, Fas, SPA, Glomus tumor, MSLN, Neoplasm, Research, RNA, Tumor microenvironment, Abstract, AACR, CA9, Clinical trial, Cancer, CRISPR, Primer, TCR, Engineering, PSMA, Cas9, ICT, Vaccine

Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.

Key Points: 
  • Arsenal Biosciences, Inc. (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of four abstracts at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA., May 5-10, 2024.
  • AB-2100 will be studied in a phase 1/2 clinical trial as a potential therapy for clear cell renal cell carcinoma (ccRCC) ( NCT06245915 ).
  • To better characterize CAR induction and receptor turnover, we conducted a series of assays, ultimately demonstrating preclinically that all PrimeR ICT cells have the potential to induce CAR.
  • Leveraging a reductionist in vitro model system, we were also able to analyze CAR induction and receptor turnover.

AdvanCell Appoints Anna Karmann, MD, PhD as Chief Medical Officer

Retrieved on: 
Thursday, January 4, 2024
Research, Biotechnology, Other Health, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Molecular imaging, McKinsey & Company, IND, Drug development, Maastricht University, RWTH Aachen University, MBA, Alpha, MD, Doctor of Philosophy, Tsinghua University, Cancer, Investigational New Drug, Stanford University Medical Center, CA9, Patient, Radiopharmaceutical, Bristol Myers Squibb, Therapy, GPC3, Radiobiology

AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of Anna Karmann, MD, PhD as the company’s Chief Medical Officer based in San Francisco.

Key Points: 
  • AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of Anna Karmann, MD, PhD as the company’s Chief Medical Officer based in San Francisco.
  • Anna has over 15 years of experience in the biopharma industry, drug development, and clinical practice.
  • Anna holds an MD from RWTH Aachen University, a PhD from Maastricht University, and an MBA from RWTH Aachen University and Tsinghua University Beijing.
  • She gained significant clinical practice and clinical research experience at the University Medical Center Maastricht, Netherlands and Stanford University Hospital, CA, USA.

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Retrieved on: 
Tuesday, December 26, 2023
Actinium, Hart–Scott–Rodino Antitrust Improvements Act, BMY, SSTR2, Bristol Myers Squibb, Hepatocellular carcinoma, Drug development, LLP, Acquisition, Centerview Partners, SAN, Carcinoma, BofA Securities, HCC, Covington & Burling, GMP, Cancer, CA9, Growth, Patient, Therapy, GPC3, Radioactive decay, Cooley LLP, Radiation, Pharmaceutical industry

PRINCETON, N.J. and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
  • “Radiopharmaceutical therapeutics are already transforming cancer care, and RayzeBio is at the forefront of pioneering the application of this novel modality.
  • Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

 Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

Retrieved on: 
Tuesday, December 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Actinium, Hart–Scott–Rodino Antitrust Improvements Act, BMY, SSTR2, Bristol Myers Squibb, Hepatocellular carcinoma, Multimedia, Drug development, LLP, Acquisition, Centerview Partners, Carcinoma, BofA Securities, HCC, Covington & Burling, GMP, Cancer, CA9, Growth, Patient, Therapy, GPC3, Radioactive decay, Cooley LLP, Radiation, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired.
  • The transaction was unanimously approved by both the Bristol Myers Squibb and RayzeBio Boards of Directors.
  • Bristol Myers Squibb expects to finance the acquisition with primarily new debt issuance.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Press release - Air pollution: Environment Committee MEPs push for tougher rules

Retrieved on: 
Wednesday, June 28, 2023
Zero, Population, Resources and Environment Committee of the Chinese People's Political Consultative Conference, S&D, Commission, NO2, CA6, CA9, Telephone numbers in Hungary, Member of the European Parliament, Mercury, CA13, Gamer, ES, Parliament, Biodiversity, European Parliament Committee on the Environment, Public Health and Food Safety, Nitrogen dioxide, Ammonia, SO2, UFP, PM10, Particulates, Air quality guideline, Ozone, WHO, NH3, Health, Air pollution, Environment, Guideline, World Health Organization, Fossil fuel, Coal, EEA, EU

MEPs also say that upcoming reviews of this directive shall ensure full and continuous alignment with the most recent World Health Organization (WHO) Air Quality Guidelines.

Key Points: 
  • MEPs also say that upcoming reviews of this directive shall ensure full and continuous alignment with the most recent World Health Organization (WHO) Air Quality Guidelines.
  • More air quality sampling points
    The Environment Committee underlines the need to increase the number of air quality sampling points.
  • Quote
    After the vote, rapporteur Javi López (S&D, ES) said: “Addressing air pollution in Europe demands immediate action.
  • We must follow science and align our air quality standards with WHO guidelines and re-inforce some of the provisions in this directive.

ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023
Science, Research, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Abstract, Antigen, CRISPR, Gene, Intrinsic termination, PTPN2, Ovarian cancer, Integrated circuit, PSMA, Kidney cancer, Therapeutic index, CA9, Pharmacokinetics, FAS, Renal cell carcinoma, CAR, ICT, Patient, Treatment, TME, Cell, Canadian Aviation Regulations, American Society of Gene and Cell Therapy, Safety, Tumor microenvironment, Society, Synthetic biology, Pharmaceutical industry, Vaccine, Flour

The three posters will disclose features and findings on AB-2100, a novel integrated circuit T cell therapeutic candidate engineered for the treatment of kidney cancer.

Key Points: 
  • The three posters will disclose features and findings on AB-2100, a novel integrated circuit T cell therapeutic candidate engineered for the treatment of kidney cancer.
  • AB-2100 is ArsenalBio’s second pipeline program which is targeting the initiation of a phase 1 trial in 2024.
  • The following abstracts will be presented as an oral abstract session and three posters during the ASGCT annual meeting.
  • The SPA platform allows tuning of T cell biology to engineer T cell therapies with increased antitumor potency and cellular persistence.

ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress

Retrieved on: 
Friday, April 14, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Abstract, Antigen, AACR, PS, Therapy, Special Protection Area, Intrinsic termination, RCC, Neoplasm, PSMA, Kidney cancer, CA9, American Association for Cancer Research, Trial of the century, Renal cell carcinoma, CAR, ICT, Risk, Engineering, Carbonic anhydrase 9, SPA, Canadian Aviation Regulations, Ovarian cancer, Tumor microenvironment, Primer, Medical imaging, Pharmaceutical industry, Vaccine

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of six abstracts at the American Association for Cancer Research (AACR) annual meeting in Orlando, Fla., April 14-19, 2023.

Key Points: 
  • Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company engineering advanced CAR T-cell therapies for solid tumors, today announced the presentation of six abstracts at the American Association for Cancer Research (AACR) annual meeting in Orlando, Fla., April 14-19, 2023.
  • These data demonstrate the company’s continued progress towards the enhancement and clinical development of its unique integrated circuit T cell approach for diseases beyond ovarian cancer, including kidney cancer and other solid tumors.
  • This is the company's second pipeline program which is targeting the initiation of a phase 1 trial in 2024.
  • The following abstracts will be presented as poster presentations during the AACR annual meeting.

Monrol Is Partnering With Telix Pharmaceuticals, Supplying Lutetium nca Lu 177 for the Manufacturing of Clinical Doses for the Phase II STARLITE 2 Study At MSK and Manufacturing Clinical Doses for Telix’s Phase III ZIRCON Trial

Retrieved on: 
Tuesday, May 10, 2022
Science, Other Science, Pharmaceutical, Medical Supplies, Oncology, Health, Hospitals, Clinical Trials, TGA, Safety, Radionuclide, Nivolumab, Degenerative disease, Gallium, CDMO, Carbonic anhydrase, Positron emission tomography, Quality of life, Radiopharmaceutical, Technology, Nuclear medicine, Transport, CFR, ASX, PRRT, Phase, Australian Securities Exchange, Kidney cancer, Oncology, MRI, Patient, NET, Clinical trial, Lung, CA9, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MTR, Breakthrough therapy, LinkedIn, Prostate, Neoplasm, Title 21 CFR Part 11, Histology, Bristol Myers Squibb, PET/CT, Memorial Sloan Kettering Cancer Center, GMP, Movement, Cancer, MSK, Food, Radiation, CT, Diagnosis, Kidney, Prostate cancer, PET, Pharmaceutical industry, Vaccine, Medical imaging, Tax advisor, Animal, Telix, Lutetium

Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study.

Key Points: 
  • Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study.
  • Clinical doses of Telixs investigational renal cancer companion imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is also produced by Eczacbas Monrol in its Istanbul facility for the Phase III ZIRCON clinical trial.
  • ZIRCON Phase III study (Zirconium Imaging in Renal Cancer Oncology) is an international multi-centre study at 34 sites in Europe, Australia, Turkey, Canada, and the United States.
  • Telixs companion investigational diagnostic imaging agent TLX250-CDx (89Zr-DFO-girentuximab) is the subject of a global Phase III trial recruiting (ZIRCON trial, NCT03849118 ).

First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer

Retrieved on: 
Monday, December 20, 2021
Squamous cell carcinoma, TAT, TLX, GLOBE, Neck, Institute, Bladder cancer, Head, ASX, Cancer, MTR, Safety, Disease, Carbonic anhydrase, Risk, Partnership, Nuclear medicine, Industry, ICO, Company, Clear cell renal cell carcinoma, Lung, Human, Patient, CA9, Pharmaceutical industry, Medical imaging, Telix, NMIBC

(ATONCO) today announce that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Cancrologie de lOuest (ICO) in St Herblain, France.

Key Points: 
  • (ATONCO) today announce that a first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder cancer (NMIBC) at the Institut de Cancrologie de lOuest (ICO) in St Herblain, France.
  • The objective of PERTINENCE1 an investigator-led, open-label, proof of concept study, is to evaluate safety, biodistribution and dosing properties of TLX250-CDx (89Zr-DFO-girentuximab) in patients with NMIBC.
  • The PERTINENCE study builds on the Telix and ATONCO licence and development agreement announced in December 2019,2 and will be led by Dr. Caroline Rousseau at ICO.
  • It will recruit 6 patients over 12 months, with a successful outcome leading to therapeutic studies with astatine-211 (211At) for targeted alpha therapy (TAT).

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

Retrieved on: 
Monday, October 4, 2021
Neck, Food, Cancer, PET, Bladder cancer, MRI, Diagnosis, HER2, Breast cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breast, CT, Intention, Carbonic anhydrase, FDA, Aggression, Patient, ICO, TGA, Triple-negative breast cancer, LinkedIn, Degenerative disease, Head, CA9, Kidney cancer, Squamous cell carcinoma, GLOBE, Prostate cancer, Breakthrough therapy, Principal, Woman, Australian Securities Exchange, ASX, Institute, Positron emission tomography, Actinium-225, PET/CT, MTR, Metastasis, Lung, TLX, Pharmaceutical industry, Medical imaging

TNBC has a poorer prognosis than other breast cancer subtypes and is characterised by its aggressive behaviour and distinct patterns of metastasis.

Key Points: 
  • TNBC has a poorer prognosis than other breast cancer subtypes and is characterised by its aggressive behaviour and distinct patterns of metastasis.
  • Telixs core CA9 program is focused on ccRCC, the most common form of kidney cancer, and is the subject of the ZIRCON Phase III (imaging) and STARLITE Phase II (therapy) studies.
  • Telix Chief Medical Officer, Dr. Colin Hayward stated, Telix is very pleased to see a first patient dosed in this important study of TLX250-CDx in TNBC, an aggressive breast cancer subtype that is poorly served by current tracers.
  • Principal Investigator for the OPALESCENCE study, Dr. Caroline Rousseau stated, Theranostic approaches to diagnosis and treatment are transforming prostate cancer.